MARKET TALK: Ambrian Starts Drug Maker Vectura At Buy
2nd Aug 2010 14:21
1321 GMT [Dow Jones] Ambrian initiates coverage of Vectura Group (VEC.LN) with a buy rating and fair value of 98p. Analyst Chris Redhead says the drug maker is significantly undervalued. A program with Novartis (NOVN.VX) could bring the companies a significant share of the $9 billion-a-year market f
Read moreGlaxoSmithKline Consumer 2Q Net Profit Rises 30% To INR717.5 Mln
2nd Aug 2010 10:36
BANGALORE (Dow Jones)--India's GlaxoSmithKline Consumer Healthcare Ltd. (500676.BY) said Monday net profit for the second quarter jumped 30% to INR717.5 million from INR551.9 million a year earlier. Sales for the quarter through June rose 15% to INR5.37 billion from INR4.69 billion, said the ass
Read moreAurobindo Pharma Gets US OK To Sell Generic Heartburn Syrup
2nd Aug 2010 06:09
BANGALORE (Dow Jones)--Aurobindo Pharma Ltd. (524804.BY) Monday said it has received a final approval from the U.S Food and Drug Administration to sell a generic version of GlaxoSmithKline PLC's (GSK) Zantac syrup for treating heartburn. Aurobindo Pharma is ready to start selling ranitidine hydr
Read moreUPDATE: FDA Approves Vaccines for 2010-11 Flu Season
30th Jul 2010 19:57
(Update in last paragraph with list of companies making the flu vaccine.) By Shayndi Raice Of DOW JONES NEWSWIRES WASHINGTON (Dow Jones)--The U.S. Food and Drug Administration announced Friday it has approved vaccines for the 2010-2011 flu season. The latest flu vaccine will prevent
Read morePRESS RELEASE: GlaxoSmithKline Begins Distribution of Flu Vaccine to U.S. Customers for 2010-2011 Flu Season
30th Jul 2010 13:30
PHILADELPHIA, July 30 /PRNewswire-FirstCall/ -- GlaxoSmithKline (NYSE: GSK) announced today that the U.S. Food and Drug Administration's (FDA) Center for Biologics Evaluation and Research (CBER) has released the first lots of FluLaval(R) [Influenza Virus Vaccine] allowing distribution in the U.S. to
Read more2nd UPDATE: Amgen 2Q Profit Drops 5.3% As Costs Rise
29th Jul 2010 23:58
(Updates throughout with details, company comment.) By Thomas Gryta Of DOW JONES NEWSWIRES NEW YORK (Dow Jones)--Amgen Inc. (AMGN) reported a 5.3% drop in second-quarter net income, as total sales of its products dropped and spending rose in preparation of a key product launch. The T
Read moreUPDATE: Amgen 2Q Profit Drops 5.3% As Cost Rise
29th Jul 2010 22:15
(Updates throughout with details, background) By Thomas Gryta Of DOW JONES NEWSWIRES NEW YORK (Dow Jones)--Amgen Inc. (AMGN) reported a 5.3% drop in second-quarter net income, as total sales of its products dropped and spending rose in preparation of a key product launch. The Thousan
Read moreGlaxoSmithKline Gets Exclusive License For Gsk2251052 Drug
29th Jul 2010 16:18
LONDON (Dow Jones)--GlaxoSmithKline PLC (GSK.LN) said Thursday it has exercised its option to obtain an exclusive license to develop and commercialize GSK2251052, or GSK 052, formerly known as AN3365. MAIN FACTS: -GSK '052 is a novel, systemic antibiotic derived from Anacor Pharmaceuticals'
Read morePRESS RELEASE: Isis Earns $5 Million Milestone Payment From GSK for Designation of a Development Candidate to Treat an Undisclosed Rare and Serious Disease
29th Jul 2010 12:00
CARLSBAD, Calif., July 29 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals Inc. (Nasdaq: ISIS) announced today that it has earned a $5 million milestone payment from GlaxoSmithKline (NYSE: GSK) related to the designation as a development candidate of a drug to treat an undisclosed rare and serious dis
Read moreOPTIONS REPORT:Genzyme Takeover Rumors Meet With Some Skepticism
27th Jul 2010 20:30
By Brendan Conway Of DOW JONES NEWSWIRES NEW YORK (Dow Jones)--For one big options trader, the takeover chatter on Genzyme Corp. could be just that--chatter. The Cambridge, Mass., biotechnology company has been the subject of buyout rumors recently, with French drug maker Sanofi-Aventis
Read moreOn Dow Jones Investment Banker Today: Genzyme, Kirin, Booz Allen
27th Jul 2010 20:08
LONDON (Dow Jones Investment Banker)--The following columns have been published exclusively on Dow Jones Investment Banker in recent days. Many Dow Jones Investment Banker columns contain spreadsheets, video, PDFs and other supporting material. To arrange access to the best of Dow Jones news and opi
Read moreUPDATE: Merck In Talks For China Partnership >MRK
27th Jul 2010 16:09
(Updates to focus on China partnership; adds new details and background; updates stock prices) By Peter Loftus Of DOW JONES NEWSWIRES Merck & Co. (MRK) said Tuesday it was in talks with China's Sinopharm Group Co. (SHTDF, 1099.HK) for a venture to market vaccines and potentially Merck
Read moreUS HOT STOCKS: CBOE, Delta Pete, FMC Technologies, Genzyme -2-
26th Jul 2010 22:01
CBOE Holdings Inc. (CBOE, $26.50, -$0.65, -2.39%) shares fell just over a month after the company went public as several Wall Street analysts initiated coverage of the stock; most agreed that the exchange's dominant position in options is a key asset, but said competition and light trading volume wi
Read moreGlaxo To Implement New Evaluation Method For Bonus Pay
26th Jul 2010 20:58
DOW JONES NEWSWIRES GlaxoSmithKline (GSK, GSK.LN) on Monday said it will implement a new system for evaluating and compensating its sales professionals beginning next year, saying customer feedback would be a factor in determining bonuses. The pharmaceutical company said payouts will be det
Read morePRESS RELEASE: GlaxoSmithKline to Implement New Compensation Program for U.S. Sales Professionals
26th Jul 2010 20:00
PHILADELPHIA, July 26 /PRNewswire-FirstCall/ -- GlaxoSmithKline (NYSE: GSK) today confirmed that it will implement a new system for evaluating and compensating its sales professionals beginning in 2011. Under the new system, bonuses for sales professionals who work directly with healthcare profe
Read more